the specific objectives of this funding opportunity are to:

• develop structured, openly accessible, and sustainable training and mentoring platforms that build capacity in the design, delivery, and analysis of clinical trials by:
  • supporting the engagement of trainees, researchers, healthcare professionals and clinical research professionals in collaborative clinical trial training and mentoring opportunities across institutions, disciplines, jurisdictions and sectors;
  • incorporating diverse training approaches, including experiential training opportunities;
  • including diverse and inclusive approaches to training and mentoring (e.g., indigenous ways of knowing) in a meaningful and culturally-safe manner; and
  • implementing recruitment, training, and mentoring strategies to attract high-caliber trainees, researchers, healthcare professionals and clinical research professionals, including embedding and applying equity, diversity and inclusion (edi) best practices.
• support the development of skills that increase the likelihood of employability and career prospects of trainees, researchers, healthcare professionals and clinical research professionals across sectors, by integrating training on:
  • approaches to advance rigorous and responsible research (e.g., product development from discovery to commercialization; best practices in clinical trial design, recruitment, conduct and reporting; sex- and gender-based analysis plus [sgba+]; research data management, research involving indigenous peoples, ethics, unconscious bias, life cycle/life stage approaches to clinical trials);
  • grant/proposal writing, budgeting, and peer review;
  • professional development skills (including transferrable skills, such as communication, analytical thinking, problem solving, project management, leadership, etc.);
  • best practices in knowledge translation and implementation science; and
  • diverse career options and opportunities available across the different sectors (private/for profit, public and not-for-profit).
• support and contribute, where possible and relevant, to research funded through the projects component (offered through separate funding opportunities) of the ctf and participate in the pan-canadian clinical trials consortium once it is established.

the specific objectives of this funding opportunity are, in the context of the biomanufacturing and life sciences strategy, to:

• support research teams across the country in conducting clinical trials that apply intersectional study design, primary data collection, and analyses so that the outcomes and health benefits of these trials can be applied to canada's diverse population;
• support the participation of canadian sites in international clinical trials;
• promote relevant collaborations across disciplines, professions, and sectors; and
• contribute to the creation and use of health-related knowledge.

the nominee’s work/research must have been performed in canada by a canadian resident and have achieved international recognition for its contribution to the advancement of knowledge in the health sciences, health policy and/or the improvement of therapeutics and healthcare.

if you are interested in being nominated for this award, please contact dr. batia stolar, associate vice-president, research and graduate studies, at  bstolar@lakeheadu.ca

the fy22 defense appropriations act provides funding for the vision research program (vrp) to support impactful military-relevant vision research.  the managing agent for the anticipated funding opportunities is the cdmrp at the u.s. army medical research and development command (usamrdc).

the fy22 vrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website.    

applications submitted to the fy22 vrp must address one or more of the following focus areas:

• eye injury or visual dysfunction as related to military exposure. examples of military exposure may include, but are not limited to:

o   blast, penetrating, blunt, thermal, or chemical trauma

o   directed energy weapons such as laser, high-power microwaves, particle beams and ionizing radiation

• diagnosis, stabilization, and treatment of eye injuries in austere environments and prolonged field care settings
• restoration of visual function after military exposure-related vision loss or severe visual impairment

funding opportunities-fy22 vrp, congressionally directed medical research programs (cdmrp) (army.mil)

clinical trial award (cta) – preproposal due july 15, 2022

• ·     the overall lead principal investigator (pi) must be an independent investigator at or above the level of associate professor (or equivalent) with demonstrated success in leading large collaborative research project(s).
• ·     the overall lead pi must devote a minimum of 20% effort.
• ·     leaders of individual projects may be independent investigators at all academic levels (or equivalent).

each project leader, including the overall lead pi, may lead no more than one project.

• ·       preproposal is required; application submission is by invitation only.
• ·       supports studies that will yield highly impactful discoveries or major advancements in research and/or patient care.
• ·       research must address one or more of the fy22 vrp focus areas.
• ·       funding level 1 supports exploratory, high-risk/
  high-reward research in the earliest stages of development.

o   research must have the potential to yield new avenues of investigation, such as new approaches, new research tools, or new paradigms.

o   while preliminary data are not required, applicants must provide solid rationale of the research idea.

o   the investigating team must have sufficient expertise to test the idea.

• ·       funding level 2 supports the advancement of more mature research that has the potential to make significant advancements toward clinical translation.

o   preliminary data supporting the readiness and feasibility of the proposed research are required. 

• ·       pi is responsible for selecting the funding level that is most appropriate for the research proposed. the funding level should be selected based on the stage of the research project, rather than the amount of the budget.

clinical trials are not allowed.

funding level 1:

• ·    the maximum allowable funding for the entire period of performance is $260,000 for direct costs (plus indirect costs).
• ·    the maximum period of performance is 2 years.

funding level 2:

• ·    the maximum allowable funding for the entire period of performance is $750,000 for direct costs (plus indirect costs).

the maximum period of performance is 3 years.

investigator-initiated research award (iira) – preproposal due july 15, 2022

independent investigators at all academic levels (or equivalent).

• ·       preproposal is required; application submission is by invitation only.
• ·       supports studies that will yield highly impactful discoveries or major advancements in research and/or patient care.
• ·       research must address one or more of the fy22 vrp focus areas.
• ·       funding level 1 supports exploratory, high-risk/
  high-reward research in the earliest stages of development.

o   research must have the potential to yield new avenues of investigation, such as new approaches, new research tools, or new paradigms.

o   while preliminary data are not required, applicants must provide solid rationale of the research idea.

o   the investigating team must have sufficient expertise to test the idea.

• ·       funding level 2 supports the advancement of more mature research that has the potential to make significant advancements toward clinical translation.

o   preliminary data supporting the readiness and feasibility of the proposed research are required. 

• ·       pi is responsible for selecting the funding level that is most appropriate for the research proposed. the funding level should be selected based on the stage of the research project, rather than the amount of the budget.
• ·       clinical trials are not allowed.

funding level 1:

• ·    the maximum allowable funding for the entire period of performance is $260,000 for direct costs (plus indirect costs).
• ·    the maximum period of performance is 2 years.

funding level 2:

• ·    the maximum allowable funding for the entire period of performance is $750,000 for direct costs (plus indirect costs).
• ·    the maximum period of performance is 3 years.

translational research award (tra) – preproposal due july 15, 2022

independent investigators at all academic levels (or equivalent).

• ·       preproposal is required; application submission is by invitation only.
• ·       supports translational research that moves promising laboratory research into clinical applications.
• ·       research must address one or more of the fy22 vrp focus areas.
• ·       it is expected that an ind or ide application will be submitted during or by the end of the period of performance.
• ·       preliminary data are required.
• ·       may include, as a portion of the proposed research, a pilot clinical trial component that collects preliminary data to inform the feasibility, rationale, and design of subsequent clinical trials.
• ·    the maximum allowable funding for the entire period of performance is $1,000,000 for direct costs (plus indirect costs).
• ·    the maximum period of performance is 3 years.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final funding opportunity announcements available for downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420.

for email notification when announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the vrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

for more information, please contact jill sherman, international research facilitator, at intl.research@lakeheadu.ca.

the investigators in the pathogenesis of infectious disease (path) award provides $500,000 over five years to support accomplished investigators at the assistant professor level to study pathogenesis, with a focus on the interplay between human and microbial biology, shedding light on how human and microbial systems are affected by their encounters.

for more information, please contact jill sherman, international research facilitator, at  intl.research@lakeheadu.ca.

the kids brain health network (kbhn) invites early career investigators engaged in neurodevelopmental disabilities research from all disciplines to apply for the 2022 early career investigator & mentorship awards competition.

summary

• award: $50 000 per year for two years (total award $100 000) comprised of $50 000 funding from kbhn and $50 000 from an eligible partner
• award term: 24 months from september 2022 (or otherwise as negotiated).
• early career investigator eligibility: must be a faculty member or principal investigator at an eligible research institution who is an early career investigator (within five years from the date of their first research-related appointment, minus eligible delays in research). the individual must be engaged in neurodevelopmental disability research in one or more of the priority areas outlined below and can use the funds to support a postdoctoral fellow.
• types of partners required: canadian or international institutions or organizations (private, public, not-for-profit) of any type (see details below).
  • application deadline: june 13^th, 2022
  • anticipated date for award notice: july 15^th, 2022

together, brain canada and the als society of canada are pleased to announce the continuation of the discovery grant program. the purpose of this program is to invest in the best possible projects that are focused on identifying causes of, or treatments for als and/or related neurological diseases, or research focused on avenues to maximize function, minimize disability and optimize quality of life through symptom management, and support to persons or families living with als.

the 2022 als canada – brain canada discovery grant program consists of two streams that will fund novel and innovative research approaches, supported by sound rationale and a feasible experimental plan:

stream 1 : aimed at nurturing novel ideas looking to obtain preliminary data or to pursue ideas supported by very early data signals. up to six awards of up to $125,000 will be awarded in this cycle.

stream 2 : aimed at funding more ambitious projects that are supported with some level of preliminary data to justify the larger investment. up to two awards of up to $300,000 will be awarded in this cycle.

evidence clearly shows that increasing equity, diversity and inclusion (edi) in research environments enhances excellence, innovation and creativity. brain canada and als canada are committed to excellence through equity and encourage applicants of diverse backgrounds to apply to our funding opportunities. 

please refer to the terms of reference for additional details.

deadline for receipt of full applications: july 5, 2022  at 13:00 et

for more information, please contact research@als.ca.

the specific objectives of this funding opportunity are to:

• establish a pan-canadian clinical trials consortium that will enhance connections between domestic and international clinical trial networks to create efficiencies of scale and support high quality trials that are designed and sized to maximize their impact;
• increase the impact of clinical trials through improved research design, increased recruitment, and enhanced clinical trial network capacity in canada, including through the development and seed funding of new clinical trial networks where there are currently gaps;
• build clinical trial capacity through training, mentorship, methods development, and information-sharing across member networks and other components of the ctf;
• maximize research impact and knowledge mobilization within and beyond the consortium to help ensure evidence is integrated in and used to inform health policy, decision making and planning; and
• advance equitable access to clinical trials for canadians regardless of geography, race/ethnicity, and socioeconomic status.